ReviewInternational archives of allergy and immunology2024

The T-Cell Growth Factor Interleukin-2, Which Is Occasionally Targeted by Autoantibodies, Qualifies as Drug for the Treatment of Allergy, Autoimmunity, and Cancer: Collegium Internationale Allergologicum (CIA) Update 2024.

Al Nasar Ahmed Sehgal et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.